Efficacy and tolerability of subcutaneously administered immunoglobulin in myasthenia gravis: A systematic review

被引：7

作者：

Adiao, Karen Joy B. ^{[1
,2
]}

Espiritu, Adrian I. ^{[1
,2
,5
]}

Roque, Vladimir Lennin A. ^{[2
,3
,6
]}

Reyes, Jose Paciano Baltazar T. ^{[2
,4
,5
]}

机构：

[1] Univ Philippines Manila, Coll Med, Dept Neurosci, Sect Adult Neurol, Manila, Philippines

[2] Univ Philippines Manila, Philippine Gen Hosp, Manila, Philippines

[3] Univ Philippines Manila, Dept Med, Coll Med, Manila, Philippines

[4] Univ Philippines Manila, Electromyog Nerve Conduct Veloc Unit EMG NCV, Sect Adult Neurol, Dept Neurosci,Coll Med, Manila, Philippines

[5] Univ Philippines Manila, Philippine Gen Hosp, Sect Adult Neurol, Dept Neurosci,Coll Med, Taft Ave, Manila 1000, Philippines

[6] Univ Philippines Manila, Philippine Gen Hosp, Dept Med, Coll Med, Taft Ave, Manila 1000, Philippines

来源：

JOURNAL OF CLINICAL NEUROSCIENCE | 2020年 / 72卷

关键词：

Subcutaneous immunoglobulin; Myasthenia gravis; Systematic review; INTRAVENOUS IMMUNOGLOBULIN;

D O I：

10.1016/j.jocn.2019.08.113

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Subcutaneous immunoglobulin (SCIg) is an emerging therapeutic alternative in the management of myasthenia gravis (MG) due to its potential efficacy, safety, cost effectiveness and ease of administration. At present, there are no systematic reviews that summarized the effects of SCIg in patients with MG. The objective of this study is to determine the efficacy and safety of SCIg in the treatment of adult patients with myasthenia gravis. Relevant records were identified from August 2018 to January 2019 systematic search. Five relevant articles with a total of 34 patients with MG were included in this review. Data on functional disability score and adverse events were obtained. Based on the included uncontrolled studies, the functional disability scores of adult MG patients after SCIg administration showed consistent improvement. Headache and local site injection reactions were the most common adverse events reported. The evidence from limited uncontrolled studies gathered in this review showed that SCIg may improve functional disability in patients with MG. Local and mild adverse events were reported with its administration, but no systemic and serious adverse events were noted. (C) 2019 Elsevier Ltd. All rights reserved.

引用

页码：316 / 321

页数：6

共 25 条

[11]

Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]

[12] Comparison of Plasmapheresis and Intravenous Immunoglobulin as Maintenance Therapies for Juvenile Myasthenia Gravis [J].

Liew, Wendy K. M. ;

Powell, Christine A. ;

Sloan, Steven R. ;

Shamberger, Robert C. ;

Weldon, Christopher B. ;

Darras, Basil T. ;

Kang, Peter B. .

JAMA NEUROLOGY, 2014, 71 (05) :575-580

[13] Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study [J].

Markvardsen, L. H. ;

Sindrup, S. H. ;

Christiansen, I. ;

Olsen, N. K. ;

Jakobsen, J. ;

Andersen, H. .

EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (02) :412-418

[14] CLINICAL-TRIALS OF SULFONATED IMMUNOGLOBULIN PREPARATION FOR INTRAVENOUS ADMINISTRATION .2. ADVERSE REACTIONS [J].

MATSUMOTO, S ;

KOBAYASHI, N ;

GOHYA, N .

EUROPEAN JOURNAL OF PEDIATRICS, 1981, 136 (02) :167-171

[15] Disease-specific measure of quality of life for myasthenia gravis [J].

Mullins, Larry L. ;

Carpentier, Melissa Y. ;

Paul, Robert H. ;

Sanders, Donald B. .

MUSCLE & NERVE, 2008, 38 (02) :947-956

[16]

Muppidi Srikanth, 2017, J Clin Neuromuscul Dis, V18, P135, DOI 10.1097/CND.0000000000000156

[17] SUBCUTANEOUS VERSUS INTRAVENOUS IMMUNOGLOBULIN FOR CHRONIC AUTOIMMUNE NEUROPATHIES: A META-ANALYSIS [J].

Racosta, Juan M. ;

Sposato, Luciano A. ;

Kimpinski, Kurt .

MUSCLE & NERVE, 2017, 55 (06) :802-809

[18] Analysis of High-dose Intravenous Immunoglobulin Therapy in 16 Patients with Refractory Autoimmune Blistering Skin Disease: High Efficacy and No Serious Adverse Events [J].

Seidling, Vera ;

Hoffmann, Jochen H. O. ;

Enk, Alexander H. ;

Hadascrik, Eva N. .

ACTA DERMATO-VENEREOLOGICA, 2013, 93 (03) :346-349

[19] Adverse Effects of Human Immunoglobulin Therapy [J].

Stiehm, E. Richard .

TRANSFUSION MEDICINE REVIEWS, 2013, 27 (03) :171-178

[20] Meta-analysis of observational studies in epidemiology - A proposal for reporting [J].

Stroup, DF ;

Berlin, JA ;

Morton, SC ;

Olkin, I ;

Williamson, GD ;

Rennie, D ;

Moher, D ;

Becker, BJ ;

Sipe, TA ;

Thacker, SB .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (15) :2008-2012

← 1 2 3 →